HUMA

Humacyte, Inc.

7.45 USD
-0.28 (-3.68%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Humacyte, Inc. stock is up 42.18% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 July’s closed higher than June. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
18 Jul 13:38 20 Sep, 2024 7.50 CALL 243 3735
18 Jul 13:38 20 Sep, 2024 7.50 CALL 180 3735
18 Jul 13:53 16 Aug, 2024 5.00 CALL 100 825
18 Jul 15:26 19 Jul, 2024 2.50 CALL 200 222
18 Jul 16:37 16 Aug, 2024 7.50 PUT 200 434
19 Jul 13:38 16 Aug, 2024 7.50 CALL 303 2828
19 Jul 13:39 20 Sep, 2024 7.50 CALL 222 4335
19 Jul 13:40 16 Aug, 2024 7.50 CALL 166 2828
19 Jul 13:40 16 Aug, 2024 7.50 CALL 303 2828
19 Jul 13:40 16 Aug, 2024 7.50 CALL 200 2828

About Humacyte, Inc.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues. Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company was founded in 2004 and is headquartered in Durham, North Carolina.

  • Cantor Fitzgerald
    Tue Jul 2, 10:41
    buy
    confirm
  • Benchmark
    Tue Jul 2, 09:26
    buy
    confirm